Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus POLYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus POLYMOX.
BICILLIN L-A vs POLYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic